CeriBell (NASDAQ:CBLL) Hits New 52-Week Low – Here’s Why

CeriBell (NASDAQ:CBLL) shares hit a new 52-week low during trading on Monday . The company traded as low as $22.81 and last traded at $22.91, with a volume of 47261 shares trading hands. The stock had previously closed at $24.29.

Analysts Set New Price Targets

A number of research firms recently weighed in on CBLL. William Blair initiated coverage on CeriBell in a research report on Tuesday, November 5th. They set an “outperform” rating on the stock. Bank of America initiated coverage on CeriBell in a research report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 target price for the company. Canaccord Genuity Group boosted their price target on shares of CeriBell from $31.00 to $33.00 and gave the company a “buy” rating in a report on Monday, December 9th. Canaccord Genuity Group assumed coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $30.00 target price on the stock. Finally, JPMorgan Chase & Co. assumed coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price target for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $32.60.

CeriBell Price Performance

The company’s 50 day simple moving average is $27.56.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The business had revenue of $17.20 million for the quarter, compared to the consensus estimate of $17.06 million. On average, equities research analysts forecast that CeriBell will post -2.46 EPS for the current fiscal year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.